- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a…
BOSTON, 30 nov. 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq : ALBO), une société spécialisée dans les maladies rares qui développe de nouveaux modulateurs d'acides biliaires…
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late breaker provides evidence of disease modification in PFIC –…
Hochgradige statistisch signifikante Linderung von Juckreiz, dem primären Endpunkt (p=0,002)Signifikante Verringerung des Gallensäurespiegels im Serum, dem wichtigsten sekundären Endpunkt…
Miglioramento statisticamente molto significativo dell'endpoint primario del prurito (p=0,002)Significative riduzioni dell'endpoint chiave secondario dei livelli di acidi biliari nel siero…
Mejoría estadísticamente muy significativa en el criterio de valoración principal «prurito» (p = 0,002)Reducciones significativas en el criterio de valoración secundario clave «niveles de…
– New data presented at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting (NASPGHAN) – Earlier treatment with Bylvay (odevixibat) provided…
Highly statistically significant improvement in pruritus primary endpoint (p=0.002)Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)Substantial…